Insights

Market Insights

Our research team delivers institutional-quality analysis, offering clients a rigorous understanding of market dynamics, valuation trends, and emerging sector developments.

How Liquidity Stress Is Reshaping Capital Formation in Venture and Growth Equity

With over $1 trillion in NAV trapped in older fund vintages and DPI at historic lows, liquidity pressure is fundamentally changing how GPs raise capital, how growth rounds are structured, and how companies need to position themselves for exit.

Private Markets Are Becoming the New Public Markets

LP-led secondaries and GP-led continuation vehicles hit $210 billion in 2025 for the first time, as the maturing private market liquidity infrastructure allows founders and investors to raise capital and achieve exits without the IPO process.

Oil & Gas: Liquidity Is Increasingly Purchased with Control

As major banks retreat from energy lending — with Wall Street volumes down 25% in 2025 — private credit has filled the gap, but operators are finding that the new capital comes with consent rights and governance provisions that effectively give lenders co-pilot control of the business.

Middle Eastern Sovereign Capital Is Replacing Private Equity in Large-Scale Projects

The Oil Five — PIF, ADIA, Mubadala, ADQ, and QIA — deployed a combined $126 billion in 2025, accounting for 43% of global sovereign wealth investment, as Gulf capital moves from passive co-investor to deal lead across infrastructure, digital assets, and industrials.

Clinical Trials Are Moving to China Because Western Cost Curves Broke

Chinese biotechs signed $135.7 billion in out-licensing deals with Western pharma in 2025 — more than double 2024 — as the dramatically lower cost and faster timelines of Chinese Phase I trials reshape how biotech companies structure their capital raises.

What the Patent Cliff Means for Biotech Companies Seeking Capital in 2026

Over $300 billion in prescription drug revenues are expected to lose exclusivity between 2025 and 2030, forcing large pharma to accelerate M&A and creating a concentrated window of opportunity for de-risked late-stage biotech assets.

Venture Selectivity and Capital Discipline Shape Biotech Financings in 2025

Biotech remains a magnet for venture capital, yet investors have tightened their filters.

Macroeconomic Constraints and LP Liquidity Shape Venture Deployment in 2025

The startup capital formation environment in H2 2025 has decoupled from traditional sector rotation and innovation cycles.

Fabian Kis and Dimitri Dieterle on Investor Shifts and Path to Allocation

What It Takes to Raise Capital in Today’s Market: Navigating Diligence, Framing, and Investor Trust

Explore Vortex Capital

From capital formation to transaction execution, Vortex Capital delivers strategic advisory and senior-level guidance across M&A, growth equity, and debt financing transactions for lower and middle-market companies worldwide.

Our Team